Dosage ; Prevention, orally; 60mg every 4hours (total daily dose 360mg).
Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Nimotop | Bayer Schering Pharma | Bayer East Africa Ltd. | 30mg | 100 | Tablet | per tablet | KES 9,026.83 |
| Nimotop | Bayer Schering Pharma | Bayer East Africa Ltd. | 10mg | 1 | Injection | per vial | KES 2,010.73 |
| Nimodipine more info | |
|---|---|
| Mode Of Action | Calcium channel blocker |
| Drug Indication | Prevention of vascular spasm following subarachnoid haemorrhage. |
| Precautions | Avoid concomitant use of other calcium channel blockers; beta-blockers; tablets and infusion of nimodipine; grape juice. Cerebral oedema or severely raised intracranial pressure; nephrotoxic drugs; impaired renal failure; pregnancy. |
| Side Effects | Hypotension; headache; GI disturbances; thrombocytopenia; feeling of warmth; temporary increase of liver enzymes after IV infusion. |
| Dosage | Prevention, orally; 60mg every 4hours (total daily dose 360mg). This should start within 4 days of subarachnoid haemorrhage and continue for 21 days. Treatment: IV infusion via central catheter. Initially: 1mg/hour, after 2hours; 2mg/hour as long as there is no severe drop in blood pressure. |
| Special Information | A calcium channel blocker whose smooth relaxant effect preferentially acts on cerebral arteries |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM |
| Drug Sub-Category | Calcium-channel blockers |